MURRIETA, Calif., Nov. 7, 2018 /PRNewswire-PRWeb/ -- John Powers, co-founder and President of Murrieta Genomics, LLC, the Southern California genomic sequencing business incubator, is pleased to announce that Gene Tox Lab Solutions, LLC has been admitted to the incubator's program.
Gene Tox is working on providing solutions to help healthcare organizations including hospitals and clinics manage their patient population through specialized lab testing, informatics and education, all while lowering healthcare costs and increasing revenue. One of the areas that the company sees great opportunities in is the rapidly growing genomics field.
According to Gene Tox CEO Catherine Rells, "It is estimated that half of all medical expenditures are squandered because of repeat procedures, the expenses associated with traditional methods of sharing information, delays in care, errors in care or delivery, and the like. We want to provide the solutions that can curb these costs. Incorporating health informatics reduces errors, increases communication, and drives efficiency where before there was costly incompetence and obstruction."
"By incorporating genomic sequencing data into patients' records, doctors can have a clearer view into each patient's biology – leading to more accurate prevention and treatment recommendations," stated Mr. Powers. "Our goal is to help Gene Tox develop the panels that can provide the kinds of insights that doctors need to achieve better outcomes – reducing care costs at the same time."
Ms. Rells explained a few of the benefits of joining Murrieta Genomics. "We had several conversations with the founders of Murrieta Genomics and realized that being able to access both science and business experience of not only the principals but the advisory board that they have assembled would be quite advantageous. Also, we are not spending resources trying to build a lab and hire experts to develop our genomic panels. We anticipate an accelerated launch with Murrieta Genomics as a strategic partner."
About Murrieta Genomics, LLC Murrieta Genomics provides access to next generation sequencing technology for researchers in the health, veterinary, agriculture, forensics and direct to consumer industries. The company is a true business incubator, offering mentorship and guidance from both the scientific and business perspective to aspiring genomic-related entrepreneurs. The four founding principals of Murrieta Genomics have extensive background in business, finance, science and technology. They are supplemented with an advisory board and local mentors from both business and science. In addition to low-cost incubation, the company provides hands-on consulting and will provide seed funding to qualified incubator graduates and connections to next-stage funders. For more information visit http://www.murrietagenomics.com.
About Gene Tox Lab Solutions, LLC Gene Tox Lab Solutions mission is to improve patient care through providing quality lab testing services, optimal therapy, reducing traditional trial and error approaches to prescribing medication, reducing adverse drug reactions, improving the selection of drug targeting, and improving drug compliance while providing healthcare professionals with the first user-friendly reporting for genetic, toxicology and pharmacogenomic testing. The Company offers the first comprehensive, turnkey solution to genetic, pharmacogenomic, toxicology testing and data solution implementation through cutting edge testing abilities, customized service offerings, and industry-leading patient data interpretation solutions. For more information visit http://www.genetoxlabsolutions.com.
SOURCE Murrieta Genomics
Advertisement
Gene Tox is working on providing solutions to help healthcare organizations including hospitals and clinics manage their patient population through specialized lab testing, informatics and education, all while lowering healthcare costs and increasing revenue. One of the areas that the company sees great opportunities in is the rapidly growing genomics field.
Advertisement
According to Gene Tox CEO Catherine Rells, "It is estimated that half of all medical expenditures are squandered because of repeat procedures, the expenses associated with traditional methods of sharing information, delays in care, errors in care or delivery, and the like. We want to provide the solutions that can curb these costs. Incorporating health informatics reduces errors, increases communication, and drives efficiency where before there was costly incompetence and obstruction."
"By incorporating genomic sequencing data into patients' records, doctors can have a clearer view into each patient's biology – leading to more accurate prevention and treatment recommendations," stated Mr. Powers. "Our goal is to help Gene Tox develop the panels that can provide the kinds of insights that doctors need to achieve better outcomes – reducing care costs at the same time."
Ms. Rells explained a few of the benefits of joining Murrieta Genomics. "We had several conversations with the founders of Murrieta Genomics and realized that being able to access both science and business experience of not only the principals but the advisory board that they have assembled would be quite advantageous. Also, we are not spending resources trying to build a lab and hire experts to develop our genomic panels. We anticipate an accelerated launch with Murrieta Genomics as a strategic partner."
About Murrieta Genomics, LLC Murrieta Genomics provides access to next generation sequencing technology for researchers in the health, veterinary, agriculture, forensics and direct to consumer industries. The company is a true business incubator, offering mentorship and guidance from both the scientific and business perspective to aspiring genomic-related entrepreneurs. The four founding principals of Murrieta Genomics have extensive background in business, finance, science and technology. They are supplemented with an advisory board and local mentors from both business and science. In addition to low-cost incubation, the company provides hands-on consulting and will provide seed funding to qualified incubator graduates and connections to next-stage funders. For more information visit http://www.murrietagenomics.com.
About Gene Tox Lab Solutions, LLC Gene Tox Lab Solutions mission is to improve patient care through providing quality lab testing services, optimal therapy, reducing traditional trial and error approaches to prescribing medication, reducing adverse drug reactions, improving the selection of drug targeting, and improving drug compliance while providing healthcare professionals with the first user-friendly reporting for genetic, toxicology and pharmacogenomic testing. The Company offers the first comprehensive, turnkey solution to genetic, pharmacogenomic, toxicology testing and data solution implementation through cutting edge testing abilities, customized service offerings, and industry-leading patient data interpretation solutions. For more information visit http://www.genetoxlabsolutions.com.
SOURCE Murrieta Genomics
